Drug quality comes first
Research Competence and Quality
MALESCI is an Italian company with an history since 1850 in research, pharmaceutical production and scientific information; Our mission is promoting health and improving people's quality of life.
Patient health is at the center of our attention
At 18 Borgo SS Apostoli in Florence, Pietro Malesci founded a "Drugstore and Pharmacy" in 1850.
Peter's son, Carlo, inaugurated in 1896 a "Pharmaceutical Laboratory" techniques for galenic preparations and medicinal specialties. Its success and the perspicacious choice of concentrating activities on the production of drugs for the treatment of cardiovascular disease, allowed the building of a new headquarter in Campo Marte.
The first registration in Italy of a xanthine-based preparation dates back to 1946. This was destined to remain, with all its derivatives, a fundamental drug for the treatment of asthma attacks and broncho-constriction.
Malesci joined the Menarini Group. From the '80s to today, Malesci has enriched its list of high-profile molecules, belonging to the most used pharmacological classes.
Since 1990 Malesci has entered the therapy of acid-related pathologies of the upper gastrointestinal tract, launching the first molecule of the PPI's class (proton pump inhibitors).
In 2002, Malesci reached another important milestone in gastroenterology, presenting the first second-generation acid pump inhibitor to the medical class. Consistent with its cardiological tradition, Malesci counts among its products antihypertensive drugs for the prevention and treatment of the most widespread cardiovascular pathologies, with drugs with remarkable therapeutic potential. Among the therapeutic areas in which Malesci is present, that of antibiotic therapy, which is of considerable importance for the treatment of the most common infectious diseases.
In 2005, another milestone in the history of the company was the marketing of olmesartan, a molecule belonging to the class of Angiotensin-1 antagonist, effective in the treatment of arterial hypertension.
In 2012, Malesci renews its commitment in the respiratory area with a latest-generation, non-sedative antihistamine for the treatment of allergic rhinitis (and urticaria). Malesci is constantly committed to offering scientific information on its products and training to the medical class by sponsoring congresses and ECM courses relevant to the therapeutic areas of the company.
In 2019, Malesci ehnances its image in cardiology with the launch of a third generation beta blocker, a Menarini research molecule, indicated for arterial hypertension and heart failure.
Innovation and Research
Work with us
Pharmacovigilance: what does it mean to monitor drugs?
Guidelines for Scientific Information
Ethics e Compliance
We are convinced that constantly placing integrity and ethics at the foundation of our actions is the source of our strength and the key to ever-increasing success.
Who we are
Innovation & Research
Work with us